Table 3

Autoantibodies to WIBG, GABARAPL2, ZNF706 and PAD4 proteins in patients with early RA

WIBG, ZNF706 and GABARAPL2

Anti-CCP

RF

PAD4

WIBG

ZNF706

GABARAPL2

combination


RA <1 year (n = 124) vs 186 controls (AS, PsA, SLE, SSc, and healthy)

Sensitivity (%)

70

68

18.5

33

18.5

23

48

Specificity (%)

98

nd

91

98

98

96

94

PPV (%)

96

nd

57

93

85

80

84

NPV (%)

81

nd

63

69

64

65

73

RA <1 year negative for anti-CCP (n = 37) vs 186 controls (AS, PsA, SLE, SSc, and healthy)

Sensitivity (%)

0

24

11

16

11

27

43

Specificity (%)

nd

nd

91

98

98

96

94

PPV (%)

nd

nd

19

67

50

59

59

NPV (%)

nd

nd

84

86

85

87

89

RA <1 year negative for RF (n = 39) vs 186 controls (AS, PsA, SLE, SSc, and healthy)

Sensitivity (%)

23

0

10

15

15

28

44

Specificity (%)

98

nd

91

98

98

96

94

PPV (%)

69

nd

19

67

60

61

61

NPV (%)

84

nd

83

85

85

86

89

RA <1 year negative for anti-CCP and RF (n = 28) vs 186 controls (AS, PsA, SLE, SSc, and healthy)

Sensitivity (%)

0

0

4

7

11

32

39

Specificity (%)

nd

nd

91

98

98

96

94

PPV (%)

nd

nd

5

40

43

56

50

NPV (%)

nd

nd

86

87

88

90

91


WIBG, within BGCN homolog (Drosophila); GABARAPL2, GABA(A) receptor-associated protein-like 2; ZNF706, zinc finger protein 706; PAD4, peptidyl arginine deiminase 4; RA: rheumatoid arthritis; CCP, cyclic citrullinated peptide; RF, rheumatoid factor; AS, ankylosing spondylitis; PsA, psoriatic arthritis; SLE, systemic lupus eryth ematosus; SSc, systemic sclerosis; PPV, positive predictive value; NPV, negative predictive value; nd, not determined.

Charpin et al. Arthritis Research & Therapy 2013 15:R78   doi:10.1186/ar4255

Open Data